ICUI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ICU Medical Inc (ICUI) is not a strong buy for a beginner investor with a long-term horizon at this time. The company's recent financial performance shows declining revenue, net income, and EPS, which are significant concerns. While analysts have raised price targets and maintain an Overweight rating, the lack of strong positive catalysts, neutral trading sentiment, and no significant signals from proprietary trading tools suggest that waiting for clearer signs of growth or stability would be prudent. The stock may be better suited for monitoring rather than immediate investment.
The MACD is positive and contracting, indicating a potential weakening of bullish momentum. RSI is neutral at 48.927, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong directional trend. Key support is at 120.731, and resistance is at 129.804, with the current price near the pivot level of 125.268.
Analysts have raised price targets to $178-$180 and maintain Overweight ratings, citing improved business operations and achievable guidance for 2026.
Recent financials show a YoY revenue drop of -14.15%, net income decline of -33.97%, and EPS decrease of -34.02%. News of a potential fiduciary duty investigation could impact investor sentiment.
In Q4 2025, ICU Medical reported a revenue drop to $540.7M (-14.15% YoY), net income of -$15.73M (-33.97% YoY), and EPS of -0.64 (-34.02% YoY). Gross margin improved to 37.54% (+4.05% YoY), but overall financial performance remains weak.
KeyBanc and Piper Sandler have raised price targets to $180 and $178, respectively, and maintain Overweight ratings. Analysts believe the company is well-positioned for 2026 with improved operations and achievable guidance.
